Publications by authors named "M J Sarno"
Neurological and psychiatric characterization of rapid-onset dystonia-parkinsonism over time.
Parkinsonism Relat Disord
February 2025
Introduction: The onset of symptoms in Rapid-onset dystonia-parkinsonism (RDP) is typically over days to weeks and is often triggered by stressors like fever or childbirth. Limited information is available on how the motor and nonmotor symptoms evolve over the course of the disease. Our longitudinal study analyzed data from a cohort of RDP patients, documenting their symptoms across multiple visits.
View Article and Find Full Text PDFThe discriminant validity of paranoid personality disorder has been recently questioned, and paranoid presentations are now conceived of as transdiagnostic features of personality disorders (PDs). However, empirical results are inconsistent. This study investigated the link between subclinical personality disorders (except paranoid PD) and paranoid presentations, exploring how the severity of personality functioning affects this relationship.
View Article and Find Full Text PDFImmune biomarkers in cases of recurrent pregnancy loss and recurrent implantation failure.
Minerva Obstet Gynecol
December 2024
Reproductive failures, such as recurrent pregnancy loss (RPL) and recurrent implantation failures (RIF) are a major challenge for reproductive medicine. The current management of RPL and RIF cases identifies some causes for unsuccessful pregnancy in up to half of patients. Several studies have suggested that immune disorders are responsible for an important portion of unexplained cases of RPL and RIF.
View Article and Find Full Text PDFObjective: Few epidemiological studies are reported in the published literature on the incidence or prevalence of antiphospholipid syndrome (APS), and available results are heterogeneous. This study aimed to estimate the incidence and prevalence of APS in the USA, overall and by APS subtype.
Design: A retrospective analysis of APS disease incidence and a cross-sectional analysis of disease prevalence.
Article Synopsis
- Pre-exposure prophylaxis with Tixagevimab/Cilgavimab has effectively reduced COVID-19 risks in immunocompromised patients, but its efficacy is limited against the Kraken variant (XBB.1.5).
- A study involving kidney transplant patients on this treatment showed only one asymptomatic infection during a six-month follow-up, with no hospitalizations or COVID-related deaths.
- The results suggest Tixagevimab/Cilgavimab may still be a beneficial preventive option for immunocompromised individuals, underlining the need for further clinical research on this topic.